RHS offers Preimplantation Genetic Screening (PGS) and Whole Genome Amplification (WGA) services
In response to enquiries from IVF clinics, Reproductive Health Science has established a Preimplantation Genetic Screening (PGS) service. Results can be achieved for aneuploid screening using either microarray technology (aCGH) or Next Generation Sequencing (NGS).
The EmbryoCellect™ aCGH technology has been developed in-house by Reproductive Health Science Ltd (RHS) and is sold internationally as a PGS kit to IVF clinics and genetic testing laboratories.
With the launch of DOPlify™, RHS recently expanded its services to include analysis using NGS.
The PGS service is offered to clinics that are not ready to bring testing in-house, but prefer to send their samples to a service provider. As the technology developer, RHS has already accumulated many years of experience and competency with the technology it uses and its products are internationally competitive in their performance.
The PGS service is offered from the RHS head office in Adelaide, Australia.
Contact us about our PGS service, including more specific information about costs, sample preparation requirements, turnaround time, and transportation.
EmbryoCellect™ and DOPlify™ are for research use only and should not be used as a clinical diagnostic.
Please note: Clinics will need to enter into a Service Agreement with RHS prior to sending samples.
How PGS services with RHS fit into a clinical workflow
|Oocyte collection, fertilisation and culture||Other than recommending that fertilisation be achieved using Intracytoplasmic Sperm Injection (ICSI), there are no changes required for a clinic to offer PGS. Although it is possible to offer PGS on non-ICSI embryos, there is the potential for sperm contamination and the effect of this has not been validated by RHS.|
|Embryo biopsy||Any genetic test requires a small sample of cell(s) to be biopsied from the embryo. The stage and timing of the biopsy is at the sole discretion and responsibility of the clinic. After washing the embryo biopsy according to protocols provided by RHS, the cells are transferred to a tube, with the biopsy location marked on the outside of the tube. The tube is labelled and the cells are stored frozen or shipped immediately to RHS.|
|Freezing the embryo||Once the biopsy has been performed the embryos should be vitrified to allow sufficient time for transport and testing by RHS. Published data indicates that approximately 95% of vitrified embryos survive the freeze/thaw process¹ . Additionally, pregnancy rates are similar between fresh and frozen transfer cycles¹ .|
|Shipping the sample||The biopsy sample will be shipped frozen by courier to RHS, who are based in Adelaide, South Australia.|
|PGS test||In consultation and prior agreement with the clinic, RHS will use the EmbryoCellect™ or NGS using DOPlify™ to assess the chromosomal complement of the biopsy sample.|
|PGS Result||RHS will return a report of the results of the testing. The format and content of the report will be agreed with the clinic prior to commencement of the service.|
|Embryo selection, thawing and transfer||In conjunction with the clinic’s own standard practice for embryo selection, such as morphology and morphokinetics, the clinic can use PGS results to consider which embryos are most suitable for IVF transfer.|
|Minimum Sample Size||There is no minimum sample size for EmbryoCellect™ aCGH technology. However, a sample size of at least 24 for NGS analysis is required and this may initially (during the start-up phase) delay the timing for provision of results. Once the full 24 samples have been received, there is a 7 business day turn-around to us sending you the report. It is possible to process a smaller sample size but the cost per sample will be higher due to the cost of additional reagents required.|
¹ Single-embryo transfer of vitrified-warmed blastocysts yields equivalent live-birth rates and improved neonatal outcomes compared with fresh transfers, Roy TK, Bradley CK, Bowmans MC, McArthur SJ, 2014, Vol. 101 No 5, Fertility and Sterility
DOPlify™ Whole Genome Amplification (WGA) Service
When starting with limited DNA template, whole genome amplification is used to generate sufficient DNA for downstream analysis in both research and clinical amplifications. Reproductive Health Science sells a single cell WGA kit, DOPlify™ and also offers a service for single cell, multi-cell and low template or copy number DNA sample amplification by highly experienced scientists in a specialised single cell facility.
WGA by RHS' DOPlify™ kit generates a complex library and the WGA DNA generated is suitable for a wide range of applications but not limited to, Next Generation Sequencing, aCGH or primer-specific PCR and for the detection of copy number changes, segmental DNA changes, genome monitoring, SNP analysis and mitochondrial DNA mutation detection.
The success of all amplifications are assessed by RHS using agarose gel electrophoresis as part of our quality control program.
The WGA service is offered from the RHS head office in Adelaide, Australia.
Contact us about our WGA service, including more specific information about costs, sample preparation requirements, turnaround time, and transportation.
DOPlify™ is for research use only and should not be used as a clinical diagnostic.